Final Report - ANTICARB (Monoclonal ANTIbody-targeted CARBon nanobues against cancer)
Project ID: 201587Funded under: FP7-HEALTH
This is the final summary report of ANTICARB, funded under the European Commission (EC)'s Seventh Framework Programme (FP7). ANTICARB aimed to exploit the advantages offered by a novel nanotechnology platform - carbon nanotubes - and apply them to a clinically established therapeutic modality - targeted antibody therapy - for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics (oncology treatment). The project aimed to enhance the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The document reports the results achieved while describing the project context and objectives. It summarises upon the outcomes of the project giving the work performed according to the project's workplan and at the end a list of the produced publications is given.
Download application/zip (1847180)
Record Number: 14972 / Last updated on: 2013-01-18